# Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus

> **NCT02702011** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 48 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** empagliflozin medium dose
- **DRUG:** empagliflozin low dose
- **DRUG:** empagliflozin high dose
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02702011
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-20
- **Primary completion:** 2016-09-05
- **Final completion:** 2016-10-03
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2018-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02702011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02702011, "Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02702011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*